Management of Insulinoma Presenting with Recurrent Hypoglycemia

Acute Hypoglycemia Management

Give 15–20 g of rapidly absorbed carbohydrate (e.g., 4–8 oz juice or soda) to any conscious patient with hypoglycemia. – NCCN guideline (Level of evidence not specified) 3
Re‑measure capillary glucose 15–20 minutes after carbohydrate administration to determine if additional treatment is needed. – NCCN guideline (Level of evidence not specified) 3
For patients with altered consciousness or inability to ingest oral glucose, administer glucagon 1 mg subcutaneously or intramuscularly; clinical response usually occurs within 5–15 minutes, though nausea or vomiting may follow. – NCCN guideline (Level of evidence not specified) 5
If glucagon is unavailable or contraindicated, provide intravenous dextrose for severe hypoglycemia with impaired mental status. – NCCN guideline (Level of evidence not specified) 5
All individuals at risk should carry an immediate source of sugar (e.g., glucose tablets, candy, or sugary beverage). – NCCN guideline (Level of evidence not specified) 3
Educate family members and close contacts to recognize hypoglycemic symptoms and to administer emergency treatment promptly. – NCCN guideline (Level of evidence not specified) 3

Perform a supervised 48–72‑hour inpatient fast as the gold‑standard diagnostic test for suspected insulinoma. – NCCN guideline (Level of evidence not specified) 1
Diagnostic laboratory thresholds during a documented hypoglycemic episode:
- Plasma glucose < 40–45 mg/dL (some sources accept < 55 mg/dL)
- Insulin > 3 mcIU/mL (commonly > 6 mcIU/mL)
- C‑peptide ≥ 0.6 ng/mL
- Proinsulin ≥ 5 pmol/L
- Insulin‑to‑glucose ratio ≥ 0.3
  (All criteria endorsed by NCCN) 1, 2, 6, 7
Add urinary sulfonylurea screening to exclude factitious hypoglycemia. – NCCN guideline (Level of evidence not specified) 1
Approximately 5 % of insulinoma patients present only with post‑prandial hypoglycemia. – NCCN guideline (Level of evidence not specified) 8

Endoscopic ultrasound (EUS) detects roughly 82 % of pancreatic insulinomas and is the preferred initial localization modality. – NCCN guideline (Level of evidence not specified) 1
Obtain multiphasic contrast‑enhanced CT or MRI to evaluate for metastatic disease; about 90 % of insulinomas are benign and surgically curable. – NCCN guideline (Level of evidence not specified) 1
Avoid routine Octreoscan/somatostatin scintigraphy unless octreotide therapy is being contemplated, because insulinomas are often non‑avid. – NCCN guideline (Level of evidence not specified) 1
If localization remains equivocal or for recurrent disease, consider selective arterial calcium stimulation with hepatic venous sampling (Imamura‑Doppman procedure). – NCCN guideline (Level of evidence not specified) 1
Screen for MEN‑1 syndrome by measuring fasting calcium, parathyroid hormone, and prolactin; 5–10 % of insulinomas are associated with MEN‑1. – NCCN guideline (Level of evidence not specified) 1, 8

Implement dietary modification with frequent small meals to prevent fasting‑related hypoglycemia. – NCCN guideline (Level of evidence not specified) 2, 9
Use diazoxide as the primary pharmacologic agent to stabilize glucose levels before surgery. – NCCN guideline (Level of evidence not specified) 2
Everolimus may be considered as an alternative medical therapy when diazoxide is unsuitable or ineffective. – NCCN guideline (Level of evidence not specified) 6
Octreotide or lanreotide should not be administered unless the tumor is proven somatostatin‑receptor positive on scintigraphy, because these agents can suppress counter‑regulatory hormones (growth hormone, glucagon, catecholamines) and precipitate severe hypoglycemia. – NCCN guideline (Level of evidence not specified) 1, 2, 6, 7

Surgical resection is the curative treatment of choice for localized insulinoma; approximately 90 % of patients experience an indolent disease course after resection. – NCCN guideline (Level of evidence not specified) 1
Surgery may be deferred in patients with life‑limiting comorbidities or prohibitive operative risk. – NCCN guideline (Level of evidence not specified) 2

Recommend wearing a medical‑alert bracelet indicating risk for hypoglycemia/insulinoma. – NCCN guideline (Level of evidence not specified) 3